Megace Mystery: A Case of Central Adrenal Insufficiency

Abstract EN

Megestrol acetate (MA) is a synthetic progestin with both antineoplastic and orexigenic properties.

In addition to its effects on the progesterone receptor, MA also binds the glucocorticoid receptor.

Some patients receiving MA therapy have been reported to develop clinical features of glucocorticoid excess, while others have experienced the clinical syndrome of cortisol deficiency—either following withdrawal of MA therapy or during active treatment.

We describe a patient who presented with clinical and biochemical features of central adrenal insufficiency.

Pituitary function was otherwise essentially normal, and the etiology of the isolated ACTH suppression was initially unclear.

The use of an exogenous glucocorticoid was suspected but was initially denied by the patient; ultimately, the culprit medication was uncovered when a synthetic steroid screen revealed the presence of MA.

The patient’s symptoms improved after she was switched to hydrocortisone.

Clinicians should be aware of the potential effects of MA on the hypothalamic-pituitary-adrenal (HPA) axis.